Novo Nordisk (NVO) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the use of Alhemo to more haemophilia patients.
The update would allow Alhemo to treat adults and children aged 12 and up with severe haemophilia A or moderate to severe haemophilia B without inhibitors.
The recommendation is based on a phase 3 trial that showed Alhemo significantly reduced spontaneous and traumatic bleeding compared with no prophylaxis.
The treatment also showed a favorable safety profile when delivered via a pen-injector device.
Novo Nordisk said it expects the European Commission to approve the label update within about two months.
The company's shares were up 1% in recent trading.
Price: 71.44, Change: +0.71, Percent Change: +1.00
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。